Orchestra BioMed develops medical device therapies for high blood pressure and artery disease, working with large device makers such as Medtronic. OBIO reports earnings on Mon, Nov 9, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print.
Prices, price targets and earnings estimates for OBIO are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OBIO is in one of them and how their past OBIO trades turned out.
Orchestra BioMed is a biomedical company based in New Hope, Pennsylvania, that develops medical device therapies. Its main candidates are AVIM Therapy, a bioelectronic treatment for high blood pressure that can be added to cardiac pacemakers as a software update, and Virtue SAB, a drug and device balloon for treating narrowed arteries. The company works with large medical device makers, including Medtronic, to bring these technologies to patients. Both products are still in clinical study and have not yet been approved by regulators.
